Immunovant’s FcRn drug fails in a pair of Phase 3 trials in thyroid eye diseasenews2026-04-02T09:54:01+00:00April 2nd, 2026|Endpoints News|
Gilead ends a Phase 2/3 trial of long-acting HIV pillsnews2026-04-01T23:18:50+00:00April 1st, 2026|Endpoints News|
To counter China, FDA chief wants to speed new drug trial processnews2026-04-01T19:15:42+00:00April 1st, 2026|Endpoints News|
How a 20-year old asthma drug is boosting food allergy researchnews2026-04-01T15:04:06+00:00April 1st, 2026|Endpoints News|
Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubtsnews2026-04-01T11:10:33+00:00April 1st, 2026|Endpoints News|
AstraZeneca’s next-gen hopeful for a rare bone condition fails pivotal trialnews2026-03-31T19:21:51+00:00March 31st, 2026|Endpoints News|
Astellas doesn’t pick up AviadoBio’s gene therapy, but nonprofit funding will move it forwardnews2026-03-31T15:33:37+00:00March 31st, 2026|Endpoints News|
Merck joins forces with Infinimmune to find therapeutic antibodiesnews2026-03-31T12:00:11+00:00March 31st, 2026|Endpoints News|
PepGen’s muscle disease program posts poor mid-stage results as one patient’s data get markedly worsenews2026-03-31T11:26:04+00:00March 31st, 2026|Endpoints News|
ViiV R&D head Kimberly Smith heads to retirement after three decades in HIV carenews2026-03-31T11:20:05+00:00March 31st, 2026|Endpoints News|
